Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., June 29, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced initial ATA188 Phase 1 safety results for patients with progressive multiple sclerosis (MS) at the 5th Congress of the European Academy of Neurology (EAN) in Oslo, Norway. ATA188, Atara’s off-the-shelf, allogeneic T-cell immunotherapy, targets specific Epstein-Barr virus (EBV) antigens believed to play an important role in the pathogenesis of MS. The primary objective of Atara’s ongoing ATA188 Phase 1, dose-escalating clinical study is to evaluate safety and tolerability for patients with progressive MS. Initial safety results as of April 8, 2019, showed that the first three ATA188 dose cohorts were well tolerated with no dose-limiting toxicities and no =3 grade treatment-related, treatment-emergent adverse events
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceBusiness Wire
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $13.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress [Yahoo! Finance]Yahoo! Finance
ATRA
Earnings
- 11/12/24 - Beat
ATRA
Analyst Actions
- 11/13/24 - Canaccord Genuity
ATRA
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- ATRA's page on the SEC website